DARZALEX® Redefining Approaches in Early-Line Multiple Myeloma Treatment
NDMM TRANSPLANT-INELIGIBLE PATIENTS
DARZALEX® + VMP
(bortezomib + melphalan +
NDMM = newly diagnosed multiple myeloma.
AFTER 2 PRIOR THERAPIES*
DARZALEX® + Pd
*Prior therapies included lenalidomide and a proteasome inhibitor (PI).
AFTER 3 PRIOR THERAPIES†
†Prior therapies included a PI and an immunomodulatory agent or patients were double-refractory to a PI and an immunomodulatory agent.
Extensive clinical experience in multiple myeloma1
>52,000 Patients Treated
Estimated Worldwide Since Approval2‡
1166 Patients Treated With DARZALEX® in Clinical Trials1
6 Registrational Trials in Multiple Myeloma1§
‡As of June 2018. Estimate based on projected patients, calculations of demand, and duration of treatment.
§Includes 3 large, phase 3 clinical trials.
DARZALEX® is a CD38-targeted cytolytic antibody indicated1:
- in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
- in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy
- in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI)
- as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent
Revlimid® and Pomalyst® are registered trademarks of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.